Cargando…

Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn’s disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose–response trial

INTRODUCTION: The medical treatment options for patients with Crohn’s disease (CD) are limited and patients resistant to those therapies are left requiring surgical operations that usually only achieve some symptomatic relief. Mesenchymal stem cells (MSC) have been shown to be effective for the trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otagiri, Shinsuke, Ohnishi, Shunsuke, Miura, Arisa, Hayashi, Hiroshi, Kumagai, Izumi, Ito, Yoichi M, Katsurada, Takehiko, Nakamura, Shiro, Okamoto, Rika, Yamahara, Kenichi, Cho, Kyu Yong, Isoe, Toshiyuki, Sato, Norihiro, Sakamoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001910/ https://www.ncbi.nlm.nih.gov/pubmed/29915666 http://dx.doi.org/10.1136/bmjgast-2018-000206

Ejemplares similares

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Inability to walk: a rare presentation of Crohn’s disease
por: Hoekstra, Elmer, et al.
Publicado: (2020)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag
por: McLellan, Paul, et al.
Publicado: (2023)

Therapeutic Effect of Vitamin D Supplementation in a Pilot Study of Crohn's Patients
por: Yang, Linlin, et al.
Publicado: (2013)

Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach
por: Pérez-Brocal, Vicente, et al.
Publicado: (2013)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
por: Fernandes, Samuel Raimundo, et al.
Publicado: (2022)

Understanding progression of strictures in ileal Crohn's disease—The importance of setting methodological standards
por: Tavares de Sousa, Helena, et al.
Publicado: (2022)

Editorial: Postoperative management of Crohn's disease: One size does not fit all
por: Domènech, Eugeni, et al.
Publicado: (2023)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Crohn's disease related strictures in cross‐sectional imaging: More than meets the eye?
por: Sleiman, Joseph, et al.
Publicado: (2022)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Validation of stricture length, duration and obstructive symptoms as predictors for intervention in ileal stricturing Crohn's disease
por: El Ouali, Sara, et al.
Publicado: (2022)

Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort study
por: Podmore, Bélène, et al.
Publicado: (2023)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Developing in vitro expanded CD45RA(+) regulatory T cells as an adoptive cell therapy for Crohn's disease
por: Canavan, James B, et al.
Publicado: (2016)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014
por: Akhuemonkhan, Eboselume, et al.
Publicado: (2017)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Crohn’s disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial
por: Raman, Maitreyi, et al.
Publicado: (2022)

Hyperbaric oxygen therapy: More hope than hype for future treatment of perianal fistulizing Crohn's disease?
por: Armuzzi, Alessandro, et al.
Publicado: (2022)

Self‐reported treatment effectiveness for Crohn's disease using a novel crowdsourcing web‐based platform
por: Engel, Tal, et al.
Publicado: (2023)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nfchpvrls2gj7qu5ldj54n4n4p